Список проголосовавших за комментарий " MEDNAX downgraded to Neutral at Robert W. Baird; tgt $72 (70.10)Robert W. Baird downgrades MD to Neutral from Outperform and sets target price at $72 as (1) MD is 20% off its 2016 bottom and 10% higher vs. its recent 4Q16 miss; (2) organic growth remains weak, and <strong>firm's proprietary birth data points to worsening trends</strong>; (3) MD carries a sector high historical and relative EBITDA valuation and (4) 2017 sets up to be overly reliant on M&A. In short, the risk/reward just feels more balanced as the stock nudges up against price target. <strong>They take this opportunity to opine on a multitude of cross-currents impacting Children's Services.</strong>"